French MedTech startup SafeHeal, a medical gadget innovator remodeling colorectal surgical procedure, immediately introduced a €10 million extension of its oversubscribed €35 million Sequence C financing spherical.
The extension is led by Asabys Companions by way of its Sabadell Asabys II fund, which joins a syndicate that features Sofinnova Companions, Photo voltaic Eclipse, Gideon Strategic Companions, Polis, and M&L Healthcare.
“We’re delighted to welcome Asabys Companions because the lead investor on this Sequence C extension,” mentioned Chris Richardson, President & CEO of SafeHeal. “Their addition strengthens our strategic capabilities in MedTech and demonstrates our rising momentum as we advance towards FDA approval and EU industrial launch. We’re equally grateful for the continued assist from Gideon Strategic Companions and all the syndicate of world-class traders.”
Based in 2015, SafeHeal is a medical gadget firm growing Colovac, a tool meant as a substitute for diverting ostomy in sufferers present process colorectal surgical procedure.
Colovac is a versatile endoluminal bypass sheath designed to cut back the contact of fecal content material on the anastomotic web site following colorectal surgical procedure. The gadget is positioned endoluminally and is totally reversible.
The gadget stays in place for about 10 days, till the physique’s pure therapeutic and tissue restore processes are full, after which it’s eliminated throughout an endoscopic process with out the necessity for a second surgical intervention.
This permits sufferers to renew their regular life with out the stigma and problems related to an ostomy process.
As a part of the financing, Josep Ll. Sanfeliu, Managing Associate and co-founder of Asabys, will be part of SafeHeal’s Board of Administrators.
Sanfeliu commented: “Asabys is an formidable and fast-growing funding agency dedicated to supporting world-class healthcare innovation throughout Europe and past. We’re proud to hitch SafeHeal’s investor syndicate, reflecting our perception in each the excellent group and the transformative affect of Colovac for sufferers dealing with colorectal most cancers surgical procedure.
“We look ahead to working carefully with SafeHeal’s administration and our fellow traders to assist carry this essential expertise to sufferers worldwide.”
The brand new capital elevate will additional speed up SafeHeal’s pivotal U.S. IDE research and assist the deliberate industrial launch of Colovac within the EU.
